Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer

被引：21

作者：

Lee, Michelle J. ^{[1
]}

Jin, Nan ^{[2
]}

Grandis, Jennifer R. ^{[2
]}

Johnson, Daniel E. ^{[2
]}

机构：

[1] Univ Calif San Francisco, Sch Med, San Francisco, CA USA

[2] Univ Calif San Francisco, Dept Otolaryngol, San Francisco, CA 94143 USA

来源：

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH | 2020年 / 1867卷 / 06期

基金：

美国国家卫生研究院;

关键词：

GSK-3; PI3K; PIK3CA; Head and neck squamous cell carcinoma; HNSCC; SQUAMOUS-CELL CARCINOMA; PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR; GLYCOGEN-SYNTHASE KINASE-3; ADVANCED SOLID TUMORS; PHASE-I; PIK3CA MUTATIONS; RAPAMYCIN INHIBITOR; PATHWAY INHIBITORS; MAMMALIAN TARGET; DUAL INHIBITOR;

D O I：

10.1016/j.bbamcr.2020.118679

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Head and neck squamous cell carcinoma (HNSCC) is a highly morbid, genetically unstable disease derived from the mucoepithelium of the upper aerodigestive tract. Recent characterization of this disease has implicated the PI3K-Akt-mTOR pathway as one of the most frequently dysregulated pathways. As such, there are several classes of PI3K inhibitors currently undergoing clinical trials. In this article, we review the PI3K pathway, mutations of this pathway in HNSCC, drugs that target PI3K, the impact of these agents on the PI3K and GSK-3 signaling axes, ongoing clinical trials evaluating PI3K inhibitors, and the challenges of using these drugs in the clinic. This article is part of a Special Issue entitled: GSK-3 and related kinases in cancer, neurological and other disorders edited by James McCubrey, Agnieszka Gizak and Dariusz Rakus.

引用

页数：10

共 50 条

[21] Targeting PI3K in neuroblastoma [J].

Volker Spitzenberg ;

Christian König ;

Susanne Ulm ;

Romina Marone ;

Luise Röpke ;

Jörg P. Müller ;

Michael Grün ;

Reinhard Bauer ;

Ignacio Rubio ;

Matthias Paul Wymann ;

Astrid Voigt ;

Reinhard Wetzker .

Journal of Cancer Research and Clinical Oncology, 2010, 136 :1881-1890

[22] Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers [J].

Lui, Vivian W. Y. ;

Hedberg, Matthew L. ;

Li, Hua ;

Vangara, Bhavana S. ;

Pendleton, Kelsey ;

Zeng, Yan ;

Lu, Yiling ;

Zhang, Qiuhong ;

Du, Yu ;

Gilbert, Breean R. ;

Freilino, Maria ;

Sauerwein, Sam ;

Peyser, Noah D. ;

Xiao, Dong ;

Diergaarde, Brenda ;

Wang, Lin ;

Chiosea, Simion ;

Seethala, Raja ;

Johnson, Jonas T. ;

Kim, Seungwon ;

Duvvuri, Umamaheswar ;

Ferris, Robert L. ;

Romkes, Marjorie ;

Nukui, Tomoko ;

Patrick Kwok-Shing Ng ;

Garraway, Levi A. ;

Hammerman, Peter S. ;

Mills, Gordon B. ;

Grandis, Jennifer R. .

CANCER DISCOVERY, 2013, 3 (07) :761-769

[23] Targeting PI3K in cancer: any good news? [J].

Martini, Miriam ;

Ciraolo, Elise ;

Gulluni, Federico ;

Hirsch, Emilio .

FRONTIERS IN ONCOLOGY, 2013, 3

[24] Targeting PI3K/Akt/mTOR signaling in cancer [J].

Porta, Camillo ;

Paglino, Chiara ;

Mosca, Alessandra .

FRONTIERS IN ONCOLOGY, 2014, 4

[25] Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer [J].

McCubrey, James A. ;

Rakus, Dariusz ;

Gizak, Agnieszka ;

Steelman, Linda S. ;

Abrams, Steve L. ;

Lertpiriyapong, Kvin ;

Fitzgerald, Timothy L. ;

Yang, Li V. ;

Montalto, Giuseppe ;

Cervello, Melchiorre ;

Libra, Massimo ;

Nicoletti, Ferdinando ;

Scalisi, Aurora ;

Torino, Francesco ;

Fenga, Concettina ;

Neri, Luca M. ;

Marmiroli, Sandra ;

Cocco, Lucio ;

Martelli, Alberto M. .

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2016, 1863 (12) :2942-2976

[26] Targeting the PI3K signaling pathway in cancer therapy [J].

Bartholomeusz, Chandra ;

Gonzalez-Angulo, Ana Maria .

EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 (01) :121-130

[27] Emerging strategies for targeting PI3K in gynecologic cancer [J].

Bregar, Amy J. ;

Growdon, Whitfield B. .

GYNECOLOGIC ONCOLOGY, 2016, 140 (02) :333-344

[28] Involvement of PI3K, GSK-3β and PPARγ in the antidepressant-like effect of folic acid in the forced swimming test in mice [J].

Budni, Josiane ;

Lobato, Kelly R. ;

Binfare, Ricardo W. ;

Freitas, Andiara E. ;

Costa, Ana Paula ;

Martin-de-Saavedra, Maria Dolores ;

Leal, Rodrigo B. ;

Lopez, Manuela G. ;

Rodrigues, Ana Lucia S. .

JOURNAL OF PSYCHOPHARMACOLOGY, 2012, 26 (05) :714-723

[29] Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer [J].

Fumarola, Claudia ;

Bonelli, Mara A. ;

Petronini, Pier Giorgio ;

Alfieri, Roberta R. .

BIOCHEMICAL PHARMACOLOGY, 2014, 90 (03) :197-207

[30] The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models [J].

D'Amato, V. ;

Rosa, R. ;

D'Amato, C. ;

Formisano, L. ;

Marciano, R. ;

Nappi, L. ;

Raimondo, L. ;

Di Mauro, C. ;

Servetto, A. ;

Fusciello, C. ;

Veneziani, B. M. ;

De Placido, S. ;

Bianco, R. .

BRITISH JOURNAL OF CANCER, 2014, 110 (12) :2887-2895

← 1 2 3 4 5 →